|
US5668255A
(en)
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
EP0642582A1
(en)
|
1992-05-22 |
1995-03-15 |
Dana Farber Cancer Institute |
Hybrid siv/hiv-1 viral vectors and monkey model for aids
|
|
WO1994012629A1
(en)
|
1992-12-02 |
1994-06-09 |
Baylor College Of Medicine |
Episomal vectors for gene therapy
|
|
ES2310924T3
(es)
|
1993-07-13 |
2009-01-16 |
Centelion |
Vectores adenovirales defectivos y utilizacion en terapia genica.
|
|
AU8828598A
(en)
|
1997-08-15 |
1999-03-08 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
AU1124499A
(en)
|
1997-10-28 |
1999-05-17 |
Maxygen, Inc. |
Human papillomavirus vectors
|
|
EP1064393B1
(en)
|
1998-03-20 |
2004-12-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
DE69940521D1
(de)
|
1998-10-01 |
2009-04-16 |
Univ Southern California |
Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
|
|
US6156514A
(en)
|
1998-12-03 |
2000-12-05 |
Sunol Molecular Corporation |
Methods for making recombinant cells
|
|
US6410013B1
(en)
|
1999-01-25 |
2002-06-25 |
Musc Foundation For Research Development |
Viral vectors for use in monitoring HIV drug resistance
|
|
WO2000072886A1
(en)
|
1999-05-26 |
2000-12-07 |
Dana-Farber Cancer Institute, Inc. |
Episomally replicating lentiviral vectors
|
|
WO2001083797A2
(en)
|
2000-04-28 |
2001-11-08 |
Avigen, Inc. |
Polynucleotides for use in recombinant adeno-associated virus virion production
|
|
EP1282449A2
(en)
|
2000-05-12 |
2003-02-12 |
The Regents Of The University Of California |
Treatment of human papillomavirus (hpv)-infected cells
|
|
WO2001091802A1
(en)
|
2000-05-30 |
2001-12-06 |
Baylor College Of Medicine |
Chimeric viral vectors for gene therapy
|
|
NO314588B1
(no)
|
2000-09-04 |
2003-04-14 |
Bionor Immuno As |
HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
|
|
US7122181B2
(en)
|
2000-12-19 |
2006-10-17 |
Research Development Foundation |
Lentiviral vector-mediated gene transfer and uses thereof
|
|
US20030119770A1
(en)
|
2001-08-02 |
2003-06-26 |
Zhennan Lai |
Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors
|
|
AU2002323270A1
(en)
|
2001-08-18 |
2003-03-03 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
|
US7737124B2
(en)
|
2001-09-13 |
2010-06-15 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
|
|
US20070203333A1
(en)
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
EP1495141A4
(en)
|
2002-03-20 |
2006-03-22 |
Massachusetts Inst Technology |
THERAPY OF HIV
|
|
AU2003237159A1
(en)
|
2002-04-30 |
2003-11-17 |
University Of Florida |
Treatment for phenylketonuria
|
|
US20040161412A1
(en)
|
2002-08-22 |
2004-08-19 |
The Cleveland Clinic Foundation |
Cell-based VEGF delivery
|
|
DK1545204T3
(en)
|
2002-09-06 |
2016-11-14 |
The Government Of The Us Secretary Dept Of Health And Human Services |
Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
|
|
ES2334125T3
(es)
|
2002-11-04 |
2010-03-05 |
University Of Massachusetts |
Interferencia de arn especifico de alelos.
|
|
AU2003283174A1
(en)
|
2002-12-11 |
2004-06-30 |
Cytos Biotechnology Ag |
Method for protein production
|
|
WO2004104591A2
(en)
|
2003-05-23 |
2004-12-02 |
Institut National De La Sante Et De La Recherche Medicale |
Improvements to gamma delta t cell-mediated therapy
|
|
WO2005005644A1
(en)
|
2003-07-11 |
2005-01-20 |
Cytos Biotechnology Ag |
Gene expression system
|
|
US20050019927A1
(en)
|
2003-07-13 |
2005-01-27 |
Markus Hildinger |
DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
|
|
US20050138677A1
(en)
|
2003-09-16 |
2005-06-23 |
Pfister Herbert J. |
Transgenic animal model for the treatment of skin tumors
|
|
US20070275010A1
(en)
|
2003-09-18 |
2007-11-29 |
Mark Feinberg |
Mva Vaccines
|
|
WO2005033282A2
(en)
|
2003-10-01 |
2005-04-14 |
Pharmacia & Upjohn Company Llc |
Polyamide compositions and therapeutic methods for treatment of human papilloma virus
|
|
US20080039413A1
(en)
|
2003-10-21 |
2008-02-14 |
Morris David W |
Novel compositions and methods in cancer
|
|
WO2005081911A2
(en)
|
2004-02-25 |
2005-09-09 |
Dana-Farber Cancer Institute, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α
|
|
WO2005085443A2
(en)
|
2004-03-01 |
2005-09-15 |
Massachusetts Institute Of Technology |
Rnai-based therapeutics for allergic rhinitis and asthma
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
WO2005118802A2
(en)
|
2004-06-03 |
2005-12-15 |
The Regents Of The University Of California |
Targeting pseudotyped retroviral vectors
|
|
US20080131940A1
(en)
|
2004-06-25 |
2008-06-05 |
Robert Chiu |
Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
|
|
EP1789447B1
(en)
|
2004-08-16 |
2012-04-25 |
Immune Disease Institute, Inc. |
Method of delivering rna interference and uses thereof
|
|
US7358361B2
(en)
|
2004-10-08 |
2008-04-15 |
The Board Of Trustees Of The University Of Illinois |
Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
|
|
EP1647595A1
(en)
|
2004-10-15 |
2006-04-19 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Nucleic acids against viruses, in particular HIV
|
|
JP2008518591A
(ja)
|
2004-11-02 |
2008-06-05 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
複製欠損アデノウイルスベクターの製造のためのアデノウイルスアンプリコンおよびプロデューサー細胞、その製造方法および用途
|
|
US7790446B2
(en)
|
2005-02-11 |
2010-09-07 |
Kosagen Cell Factory Oü |
Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
|
|
EP1858332A4
(en)
|
2005-02-16 |
2011-06-22 |
Lentigen Corp |
LENTIVIRUS VECTORS AND ITS USE
|
|
PL2002003T3
(pl)
|
2005-05-27 |
2016-06-30 |
Ospedale San Raffaele Srl |
Wektor genetyczny zawierający mi-RNA
|
|
US20070032443A1
(en)
|
2005-08-02 |
2007-02-08 |
Jaeseob Kim |
Therapy for Alzheimer's disease
|
|
WO2007015122A1
(en)
|
2005-08-02 |
2007-02-08 |
Genexel, Inc. |
Therapy for alzheimer’s disease
|
|
US20070105835A1
(en)
*
|
2005-11-07 |
2007-05-10 |
Kazantsev Aleksey G |
Compositions and methods for modulating poly(ADP-ribose) polymerase activity
|
|
WO2007133674A2
(en)
|
2006-05-12 |
2007-11-22 |
Lentigen Corporation |
Lentiviral vector compositions, methods and applications
|
|
US8535897B2
(en)
|
2006-06-19 |
2013-09-17 |
The Trustees Of Columbia University In The City Of New York |
Assays for non-apoptotic cell death and uses thereof
|
|
US20080003225A1
(en)
|
2006-06-29 |
2008-01-03 |
Henri Vie |
Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
|
|
WO2008008719A2
(en)
|
2006-07-10 |
2008-01-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the myc gene
|
|
EP1878440A1
(en)
|
2006-07-13 |
2008-01-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
|
|
CN101516365A
(zh)
|
2006-07-26 |
2009-08-26 |
诺瓦提斯公司 |
十一异戊二烯基焦磷酸酯合酶的抑制剂
|
|
US20080199961A1
(en)
|
2006-08-25 |
2008-08-21 |
Avi Biopharma, Inc. |
ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
|
|
EP2426142A3
(en)
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
ES2639568T3
(es)
|
2007-01-23 |
2017-10-27 |
Janssen Pharmaceutica Nv |
Método para diseñar un régimen farmacológico para pacientes infectados con el VIH
|
|
EP2203460A4
(en)
|
2007-04-12 |
2012-03-14 |
Univ Illinois |
BIPHOSPHONATE COMPOUNDS AND METHODS WITH INCREASED POTENTIAL FOR MULTIPLE OBJECTIVES, INCLUDING FPPS, GGPPS AND DPPS
|
|
US20080293142A1
(en)
|
2007-04-19 |
2008-11-27 |
The Board Of Regents For Oklahoma State University |
Multiple shRNA Expression Vectors and Methods of Construction
|
|
EP2008656A1
(en)
|
2007-06-28 |
2008-12-31 |
Bergen Teknologioverforing AS |
Compositions for the treatment of hyperphenylalaninemia
|
|
US20110177155A1
(en)
|
2007-08-21 |
2011-07-21 |
Immune Disease Institute, Inc. |
Methods of delivery of agents to leukocytes and endothelial cells
|
|
EP2090659A1
(en)
|
2008-02-14 |
2009-08-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Infectious particle, process for its preparation and use thereof
|
|
GB0810209D0
(en)
|
2008-06-04 |
2008-07-09 |
Cambridge Entpr Ltd |
Pluripotency associated epigenetic factor
|
|
US8629334B2
(en)
|
2008-07-16 |
2014-01-14 |
University Of Florida Research Foundation, Inc. |
Viral-based transient-expression vector system for trees
|
|
WO2010022195A2
(en)
|
2008-08-20 |
2010-02-25 |
Virxsys Corporation |
Non-integrating lenti/adeno-associated virus hybrid vector system
|
|
US8871515B2
(en)
|
2008-09-17 |
2014-10-28 |
Isogenis, Inc. |
Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
|
|
WO2010045659A1
(en)
|
2008-10-17 |
2010-04-22 |
American Gene Technologies International Inc. |
Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
|
|
NZ591391A
(en)
*
|
2008-10-22 |
2012-10-26 |
Quark Pharmaceuticals Inc |
Non-invasive methods for treating eye disorders using a topical oligonucleotide composition
|
|
AU2009308707A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
|
WO2010051521A1
(en)
|
2008-10-31 |
2010-05-06 |
Lentigen Corporation |
Cell therapy product for the treatment of hiv infection
|
|
WO2011071476A2
(en)
|
2008-11-14 |
2011-06-16 |
Life Technologies Corporation |
Compositions and methods for engineering cells
|
|
EP2191834A1
(en)
|
2008-11-26 |
2010-06-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Compositions and methods for treating retrovirus infections
|
|
CN102438631A
(zh)
|
2009-04-09 |
2012-05-02 |
史坦赛特股份有限公司 |
抗hiv干细胞及其用途
|
|
KR20120088542A
(ko)
|
2009-04-13 |
2012-08-08 |
아프세스 게엠베하 & 씨오. 카게 |
종양 치료를 위한 조작된 중간엽 줄기세포 및 이를 사용하는 방법
|
|
EP2425001A4
(en)
|
2009-04-30 |
2012-11-14 |
Univ California |
ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
|
|
DK3329772T3
(da)
|
2009-07-15 |
2020-01-27 |
Calimmune Inc |
Dobbeltvektor til inhibering af human immundefektvirus
|
|
EP2295543A1
(en)
*
|
2009-09-11 |
2011-03-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Method for the preparation of an influenza virus
|
|
WO2011066578A1
(en)
|
2009-11-30 |
2011-06-03 |
American Gene Technologies International Inc. |
Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
|
|
CN101805750B
(zh)
|
2009-12-29 |
2011-11-30 |
浙江大学 |
法呢基焦磷酸合成酶rna干扰重组慢病毒载体构建及用途
|
|
JP5300152B2
(ja)
|
2010-02-02 |
2013-09-25 |
株式会社Ｎｔｔファシリティーズ |
防火扉
|
|
CA2790426A1
(en)
|
2010-02-18 |
2011-08-25 |
Emory University |
Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
|
|
WO2011119942A1
(en)
|
2010-03-25 |
2011-09-29 |
Vistagen Therapeutics, Inc. |
Induction of ips cells using transient episomal vectors
|
|
WO2011133687A2
(en)
|
2010-04-20 |
2011-10-27 |
President And Fellows Of Harvard College |
Methods and compositions for inhibition of beta2-adrenergic receptor degradation
|
|
AU2011242576B2
(en)
|
2010-04-23 |
2016-03-31 |
Cold Spring Harbor Laboratory |
Novel structurally designed shRNAs
|
|
WO2012020757A1
(ja)
|
2010-08-10 |
2012-02-16 |
タカラバイオ株式会社 |
細胞集団の製造方法
|
|
WO2012048303A2
(en)
|
2010-10-07 |
2012-04-12 |
Columbia University |
METHOD FOR TREATING CANCER HARBORING A p53 MUTATION
|
|
WO2012061075A2
(en)
|
2010-10-25 |
2012-05-10 |
The Regents Of The University Of California |
Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
|
|
JP6091435B2
(ja)
|
2011-02-22 |
2017-03-08 |
カリフォルニア インスティチュート オブ テクノロジー |
アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
JP6348064B2
(ja)
|
2011-11-22 |
2018-06-27 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
効率の高いトランスジーン送達のためのウイルスベクター
|
|
US9745631B2
(en)
|
2011-12-20 |
2017-08-29 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
|
CN107982548A
(zh)
|
2012-02-07 |
2018-05-04 |
全球生物疗法有限公司 |
核酸输送的区室化方法及其组合物和应用
|
|
WO2013174404A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
WO2013182662A1
(en)
|
2012-06-06 |
2013-12-12 |
Bionor Immuno As |
Vaccine
|
|
WO2014016817A2
(en)
|
2012-07-17 |
2014-01-30 |
Universite De Geneve |
Nucleic acids for down-regulation of gene expression
|
|
EP2900835B1
(en)
|
2012-09-27 |
2025-04-30 |
Population Bio, Inc. |
Method for screening and treating developmental disorders
|
|
ES2686129T3
(es)
|
2012-11-13 |
2018-10-16 |
Codiak Biosciences, Inc. |
Administración de agentes terapéuticos
|
|
AU2013355327A1
(en)
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
US9642921B2
(en)
|
2012-12-20 |
2017-05-09 |
Tocagen Inc. |
Cancer combination therapy and recombinant vectors
|
|
WO2014117050A2
(en)
|
2013-01-26 |
2014-07-31 |
Mirimus, Inc. |
Modified mirna as a scaffold for shrna
|
|
CN103184224A
(zh)
|
2013-04-03 |
2013-07-03 |
衡阳师范学院 |
一种抗艾滋病病毒感染的三联miRNA及构建方法
|
|
EP2999797B1
(en)
|
2013-05-21 |
2018-07-04 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
|
EP3027755B1
(en)
|
2013-08-02 |
2019-10-09 |
The Regents of The University of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
WO2015042308A2
(en)
|
2013-09-18 |
2015-03-26 |
City Of Hope |
Rna-based hiv inhibitors
|
|
US20160220599A1
(en)
*
|
2013-09-27 |
2016-08-04 |
St. Michael's Hospital |
Novel lincrna and interfering nucleic acid molecules, compositions and methods and uses thereof for regulating angiogenesis and related conditions
|
|
WO2015061491A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
|
KR20230054509A
(ko)
|
2013-11-07 |
2023-04-24 |
에디타스 메디신, 인코포레이티드 |
지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
|
|
EP2878674A1
(en)
|
2013-11-28 |
2015-06-03 |
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) |
Stable episomes based on non-integrative lentiviral vectors
|
|
US11400115B2
(en)
|
2014-04-23 |
2022-08-02 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
|
DK3546585T3
(da)
|
2014-04-25 |
2025-11-03 |
Genethon |
Nukleinsyrer med en modificeret intron til brug i behandlingen af hyperbilirubinæmi
|
|
SI3689899T1
(sl)
|
2014-04-25 |
2022-01-31 |
2Seventy Bio, Inc. |
MND promotor kimeričnih antigenskih receptorjev
|
|
US20160060707A1
(en)
|
2014-08-29 |
2016-03-03 |
Immunomedics, Inc. |
Identification of Cancer Genes by In-Vivo Fusion of Human Cancer Cells and Animal Cells
|
|
DK3197472T3
(da)
|
2014-09-22 |
2021-10-18 |
Tanea Medical Ab |
Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
|
|
CA2964173A1
(en)
|
2014-10-10 |
2016-04-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
|
US10968451B2
(en)
|
2014-10-14 |
2021-04-06 |
Texas Tech University System |
Multiplexed shRNAs and uses thereof
|
|
WO2016069716A1
(en)
*
|
2014-10-30 |
2016-05-06 |
The Scripps Research Institute |
Compositions and methods comprising tyrosyl-trna synthetases and resveratrol compounds
|
|
GB201509202D0
(en)
|
2015-05-28 |
2015-07-15 |
Ge Healthcare Bio Sciences Ab |
Semi-static cell culture
|
|
US20180161455A1
(en)
|
2015-06-10 |
2018-06-14 |
American Gene Technologies International, Inc. |
Non-integrating viral delivery system and methods of use therof
|
|
EP3319631A4
(en)
|
2015-07-08 |
2019-01-09 |
American Gene Technologies International Inc. |
HIV PREMUNICATION AND IMMUNOTHERAPY
|
|
US11028369B2
(en)
*
|
2015-08-13 |
2021-06-08 |
Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. |
Induced extended pluripotent stem cells, method of making and using
|
|
CN105112370B
(zh)
|
2015-08-25 |
2019-02-05 |
杭州优善生物科技有限公司 |
一种体外刺激外周血γδT细胞高效增殖的方法及其应用
|
|
JP7059179B2
(ja)
|
2015-10-20 |
2022-04-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
遺伝子操作のための方法及び製品
|
|
US11389546B2
(en)
|
2015-12-09 |
2022-07-19 |
Modernatx, Inc. |
Heterologous UTR sequences for enhanced mRNA expression
|
|
US10137144B2
(en)
|
2016-01-15 |
2018-11-27 |
American Gene Technologies International Inc. |
Methods and compositions for the activation of gamma-delta T-cells
|
|
CA3011529A1
(en)
|
2016-01-15 |
2017-07-20 |
American Gene Technologies International Inc. |
Methods and compositions for the activation of gamma-delta t-cells
|
|
US10888613B2
(en)
|
2016-02-08 |
2021-01-12 |
American Gene Technologies International Inc. |
Method of producing cells resistant to HIV infection
|
|
ES2911448T3
(es)
|
2016-03-09 |
2022-05-19 |
American Gene Tech Int Inc |
Vectores combinados y métodos para el tratamiento del cáncer
|
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
|
EP3468617A4
(en)
|
2016-06-08 |
2020-01-22 |
American Gene Technologies International Inc. |
INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
|
|
IL300730A
(en)
|
2016-07-08 |
2023-04-01 |
American Gene Tech Int Inc |
Pre-HIV vaccine and immunotherapy
|
|
JP7176756B2
(ja)
*
|
2016-07-21 |
2022-11-22 |
アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド |
パーキンソン病を処置するためのウイルスベクター
|
|
WO2018126112A1
(en)
|
2016-12-30 |
2018-07-05 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating phenylketonuria
|
|
AU2018205388A1
(en)
|
2017-01-09 |
2019-07-18 |
American Gene Technologies International Inc. |
HIV immunotherapy with no pre-immunization step
|
|
CA3053008A1
(en)
|
2017-02-08 |
2018-08-16 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
US11820999B2
(en)
|
2017-04-03 |
2023-11-21 |
American Gene Technologies International Inc. |
Compositions and methods for treating phenylketonuria
|
|
US20200181645A1
(en)
|
2017-06-16 |
2020-06-11 |
American Gene Technologies International Inc. |
Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
|
|
CA3077355A1
(en)
|
2017-10-02 |
2019-04-11 |
American Gene Technologies International Inc. |
Vectors with promoter and enhancer combinations for treating phenylketonuria
|
|
WO2020097049A1
(en)
|
2018-11-05 |
2020-05-14 |
American Gene Technologies International Inc. |
Vector system for expressing regulatory rna
|
|
CA3137698A1
(en)
|
2019-05-31 |
2020-12-03 |
Tyler LAHUSEN |
Optimized phenylalanine hydroxylase expression
|